173 related articles for article (PubMed ID: 20814976)
1. Toxicological determination and in vitro metabolism of the designer drug methylenedioxypyrovalerone (MDPV) by gas chromatography/mass spectrometry and liquid chromatography/quadrupole time-of-flight mass spectrometry.
Strano-Rossi S; Cadwallader AB; de la Torre X; Botrè F
Rapid Commun Mass Spectrom; 2010 Sep; 24(18):2706-14. PubMed ID: 20814976
[TBL] [Abstract][Full Text] [Related]
2. Studies on the metabolism of the α-pyrrolidinophenone designer drug methylenedioxy-pyrovalerone (MDPV) in rat and human urine and human liver microsomes using GC-MS and LC-high-resolution MS and its detectability in urine by GC-MS.
Meyer MR; Du P; Schuster F; Maurer HH
J Mass Spectrom; 2010 Dec; 45(12):1426-42. PubMed ID: 21053377
[TBL] [Abstract][Full Text] [Related]
3. Toxicological investigation of forensic cases related to the designer drug 3,4-methylenedioxypyrovalerone (MDPV): Detection, quantification and studies on human metabolism by GC-MS.
Grapp M; Kaufmann C; Ebbecke M
Forensic Sci Int; 2017 Apr; 273():1-9. PubMed ID: 28187296
[TBL] [Abstract][Full Text] [Related]
4. Urine analysis of 3,4-methylenedioxypyrovalerone in opioid-dependent patients by gas chromatography-mass spectrometry.
Ojanperä IA; Heikman PK; Rasanen IJ
Ther Drug Monit; 2011 Apr; 33(2):257-63. PubMed ID: 21240056
[TBL] [Abstract][Full Text] [Related]
5. 3,4-Methylenedioxypyrovalerone (MDPV) and metabolites quantification in human and rat plasma by liquid chromatography-high resolution mass spectrometry.
Anizan S; Ellefsen K; Concheiro M; Suzuki M; Rice KC; Baumann MH; Huestis MA
Anal Chim Acta; 2014 May; 827():54-63. PubMed ID: 24832995
[TBL] [Abstract][Full Text] [Related]
6. Analytical strategy to investigate 3,4-methylenedioxypyrovalerone (MDPV) metabolites in consumers' urine by high-resolution mass spectrometry.
Ibáñez M; Pozo ÓJ; Sancho JV; Orengo T; Haro G; Hernández F
Anal Bioanal Chem; 2016 Jan; 408(1):151-64. PubMed ID: 26476921
[TBL] [Abstract][Full Text] [Related]
7. Analysis of new designer drugs and common drugs of abuse in urine by a combined targeted and untargeted LC-HR-QTOFMS approach.
Paul M; Ippisch J; Herrmann C; Guber S; Schultis W
Anal Bioanal Chem; 2014 Jul; 406(18):4425-41. PubMed ID: 24828977
[TBL] [Abstract][Full Text] [Related]
8. Cytotoxic Activity of Pyrovalerone Derivatives, an Emerging Group of Psychostimulant Designer Cathinones.
Wojcieszak J; Andrzejczak D; Woldan-Tambor A; Zawilska JB
Neurotox Res; 2016 Aug; 30(2):239-50. PubMed ID: 27295059
[TBL] [Abstract][Full Text] [Related]
9. Simultaneous determination of four designer drugs and their major metabolites by liquid chromatography-mass spectrometry.
Chen X
J Chromatogr B Analyt Technol Biomed Life Sci; 2015 Jun; 992():1-7. PubMed ID: 25939091
[TBL] [Abstract][Full Text] [Related]
10. 3,4-methylenedioxypyrovalerone (MDPV): chemistry, pharmacology and toxicology of a new designer drug of abuse marketed online.
Coppola M; Mondola R
Toxicol Lett; 2012 Jan; 208(1):12-5. PubMed ID: 22008731
[TBL] [Abstract][Full Text] [Related]
11. In vivo toxicometabolomics reveals multi-organ and urine metabolic changes in mice upon acute exposure to human-relevant doses of 3,4-methylenedioxypyrovalerone (MDPV).
Araújo AM; Carvalho M; Costa VM; Duarte JA; Dinis-Oliveira RJ; Bastos ML; Guedes de Pinho P; Carvalho F
Arch Toxicol; 2021 Feb; 95(2):509-527. PubMed ID: 33215236
[TBL] [Abstract][Full Text] [Related]
12. Determination of Synthetic Cathinones in Urine Using Gas Chromatography-Mass Spectrometry Techniques.
Hong WY; Ko YC; Lin MC; Wang PY; Chen YP; Chiueh LC; Shih DY; Chou HK; Cheng HF
J Anal Toxicol; 2016; 40(1):12-6. PubMed ID: 26410364
[TBL] [Abstract][Full Text] [Related]
13. In vitro Phase I and Phase II metabolism of α-pyrrolidinovalerophenone (α-PVP), methylenedioxypyrovalerone (MDPV) and methedrone by human liver microsomes and human liver cytosol.
Negreira N; Erratico C; Kosjek T; van Nuijs AL; Heath E; Neels H; Covaci A
Anal Bioanal Chem; 2015 Jul; 407(19):5803-16. PubMed ID: 26014283
[TBL] [Abstract][Full Text] [Related]
14. [3,4-methylene-dioxy-pyrovalerone (MDPV) epidemic?].
Kalapos MP
Orv Hetil; 2011 Dec; 152(50):2010-9. PubMed ID: 22112374
[TBL] [Abstract][Full Text] [Related]
15. Identification of phase I and II metabolites of the new designer drug α-pyrrolidinohexiophenone (α-PHP) in human urine by liquid chromatography quadrupole time-of-flight mass spectrometry (LC-QTOF-MS).
Paul M; Bleicher S; Guber S; Ippisch J; Polettini A; Schultis W
J Mass Spectrom; 2015 Nov; 50(11):1305-17. PubMed ID: 26505776
[TBL] [Abstract][Full Text] [Related]
16. Characterization of in vitro metabolites of methylenedioxypyrovalerone (MDPV): An N-oxide metabolite formation mediated by flavin monooxygenase.
Kim IS; Rehman SU; Choi MS; Jang M; Yang W; Kim E; Yoo HH
J Pharm Biomed Anal; 2016 Nov; 131():160-166. PubMed ID: 27592254
[TBL] [Abstract][Full Text] [Related]
17. New designer drug of abuse: 3,4-Methylenedioxypyrovalerone (MDPV). Findings from apprehended drivers in Finland.
Kriikku P; Wilhelm L; Schwarz O; Rintatalo J
Forensic Sci Int; 2011 Jul; 210(1-3):195-200. PubMed ID: 21477955
[TBL] [Abstract][Full Text] [Related]
18. GC-MS, GC-MS/MS and GC-IR differentiation of desoxy cathinone derivatives: Cyclic tertiary amines related to MDPV.
Abiedalla Y; DeRuiter J; Clark CR
J Chromatogr B Analyt Technol Biomed Life Sci; 2017 Mar; 1048():38-48. PubMed ID: 28199890
[TBL] [Abstract][Full Text] [Related]
19. Deaths involving methylenedioxypyrovalerone (MDPV) in Upper East Tennessee.
Wright TH; Cline-Parhamovich K; Lajoie D; Parsons L; Dunn M; Ferslew KE
J Forensic Sci; 2013 Nov; 58(6):1558-62. PubMed ID: 23919452
[TBL] [Abstract][Full Text] [Related]
20. Chiral resolution and absolute configuration of the enantiomers of the psychoactive "designer drug" 3,4-methylenedioxypyrovalerone.
Suzuki M; Deschamps JR; Jacobson AE; Rice KC
Chirality; 2015 Apr; 27(4):287-93. PubMed ID: 25727807
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
